TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued progress across its AI-enabled drug development platform at its 2025 annual investor conference, reinforcing its strategic position as the global immuno-oncology landscape enters a period of generational transition.

Global blockbuster immune-oncology products now face major patent expirations before 2030 pharmaceutical companies are either actively developing or acquiring next-generation assets that are highly combinable, scalable across multiple tumor types with potential of becoming treatment standard in different types of cancers. Senhwa is addressing this demand through an integrated strategy that combines artificial intelligence validation, precision clinical development, and global pharmaceutical partnerships.

Recently, Google DeepMind applied its latest C2S-Scale biological AI model to analyze more than 4,000 drug candidates and identified Senhwa’s lead compound Silmitasertib (CX-4945) as the most potential compound to revigorate immune system to combat with cancer. The study, supported by Google’s computing infrastructure, DeepMind’s proprietary AI models, and preclinical validation conducted by Yale University, demonstrated that CX-4945 significantly enhances tumor antigen presentation—an essential mechanism for improving immune recognition of cancer cells.

This independent third-party validation highlights the potential of CX-4945 as an immune-sensitizing agent and represents a notable milestone in the application of AI to oncology drug discovery. By addressing the long-standing challenge of immunologically “cold” tumors, which had limited response to immunotherapy, CX-4945 has a unique position in the rapidly expanding field of cold-to-hot tumor conversion.

In parallel, Senhwa continues to advance its clinical pipeline through strategic international collaboration. The company recently announced a clinical collaboration with BeOne Medicines to evaluate Senhwa’s lead candidate, Pidnarulex (CX-5461), in combination with BeOne’s commercially approved, best-in-class PD-1 inhibitor tislelizumab. The initial focus of the collaboration includes pancreatic cancer and advanced solid tumors, including immunotherapy-resistant melanoma.

CX-5461 is a first-in-class small molecule with a differentiated dual mechanism of action that stabilizes DNA G-quadruplex (G4) structures while inhibiting RNA polymerase I (Pol I). This dual activity induces replication stress in tumor cells and activates the innate immune cGAS–STING pathway, effectively converting immune-cold tumors into immune-active environments. Robust preclinical data supports the application of CX-5461 in enhancing the efficacy of existing immunotherapies and becoming the ideal candidate for combination therapy with immune-oncology products.

Senhwa believes this pathway-level, multi-target strategic approach positions CX-5461 as a potential next-generation treatment back bone in cancers where immunotherapy is used, rather than positioning the compound as a single-asset or indication-specific solution. This strategic positioning has attracted interest from global pharmaceutical companies seeking high value added platform assets, as reflected by ongoing and prior collaborations involving leading multinational partners.

Looking ahead, Senhwa expects multiple value-driving catalysts over the next one to three years, including clinical data readouts for CX-5461 and CX-4945, expansion of global partnerships, potential licensing collaborations, and increased visibility at major international medical conferences such as ASCO, AACR, and ESMO.

“Senhwa has transitioned beyond early-stage discovery and development into a company building a scalable, AI-validated oncology platform,” said the Company. “At a pivotal moment for immuno-oncology, we are focused on advancing differentiated science with the potential to create long-term value for patients, partners, and shareholders.”

Source: Senhwa Biosciences, Inc.

Source

In the news release, “(Musée Platinum Tokyo Launches DUO Hydrogen Treatment Across All Salons in Singapore)”, issued on (December 18 2025) by Musée Platinum Tokyo over PR Newswire, we are advised by the company that all mentions of “Musée Platinum Tokyo” should read “Musee Platinum Tokyo” rather than “Musée Platinum Tokyo” as originally issued inadvertently. Complete, corrected release follows:

Musee Platinum Tokyo Launches DUO Hydrogen Treatment Across All Salons in Singapore

SINGAPORE, Dec. 18, 2025 /PRNewswire/ — Musee Platinum Tokyo, a leading beauty brand with over 15 years in Singapore, has officially launched the DUO Hydrogen Treatment at all its salon locations. The non-invasive treatment is formulated for individuals with sensitive, acne-prone, eczema-prone, or reactive skin and is suitable for application to the face, scalp, and body, including delicate areas.

The hydrogen treatment offers a gentle, restorative approach to skincare, helping to calm irritation, support hydration, and enhance skin resilience. It is recommended for individuals experiencing redness, dryness, or sensitivity triggered by environmental stressors or Singapore’s humid climate.

The launch responds to growing demand among individuals in Singapore for effective yet gentle treatments that support deeper skin recovery and long-term skin resilience. The technology is designed to complement existing aesthetic services, including body hair removal, with a particular focus on improving skin health.

“We have observed an increase in individuals seeking solutions that address both visible skin concerns and underlying sensitivity,” said Karen, Operation Officer of Musee Platinum Tokyo. “The DUO Hydrogen Treatment allows us to offer a safe, non-invasive option that supports skin recovery without causing additional irritation.”

Technology Overview: Combining Hydrogen and Ozone-Based Therapies

DUO Hydrogen utilises two complementary technologies, Hydrogen Care and Ozone Care, to cleanse, soothe, and support skin that is compromised. During the Hydrogen Care stage, purified water is transformed into high-concentration hydrogen (3000PPB), which penetrates deep into the pores to neutralise free radicals and remove debris that contributes to inflammation and skin ageing.

Ozone Care enhances the treatment by delivering oxygen-rich ozone water using water plasma technology. This activates skin cells, reduces bacterial buildup, and promotes wound healing. Together, these components form a dual-action system that supports hydration, barrier repair, and clarity, qualities associated with advanced skin repair treatments.

Service Expansion and Safety Considerations

The treatment is now available at all Musee Platinum Tokyo locations in Singapore. To ensure safe application, all beauticians have completed advanced training in managing sensitive and eczema-prone skin. The treatment is fragrance-free and painless, aligning with the brand’s positioning as a provider of painless hair removal and non-invasive beauty services in Singapore.

Beauticians are trained to customise each session based on individual skin types and conditions. For individuals with active flare-ups or highly reactive skin, adjustments are made to treatment duration and application intensity. The process is designed to avoid common irritants typically found in traditional facials, making it suitable for both pre-treatment and post-treatment care.

Target Audience and Skin Benefits

Although the DUO Hydrogen Treatment was developed with eczema-prone individuals in mind, it is suitable for a broad range of skin types. Individuals with acne-prone, dry, oily, or reactive skin may benefit from regular sessions, typically recommended once every two to three weeks. For more active conditions, weekly sessions may be advised during the initial phase.

With consistent use, the treatment may help to:

• Reduce redness, irritation, and flare-ups
• Improve skin hydration and strengthen the barrier
• Smooth texture and support overall skin health
• Maintain resilient, comfortable skin across the face, scalp, and body

These benefits are particularly relevant for individuals seeking to manage chronic sensitivity while continuing with aesthetic treatments such as targeted skin therapy or hair removal.

Promotional Launch Offers

To mark the launch, Musee Platinum Tokyo is offering a limited-time trial of the DUO Hydrogen Treatment at $65 (regular price: $127.50). The introductory offer allows interested parties to experience the treatment and assess its suitability for their skin needs. Further details and booking information are available on their website.

About Musee Platinum Tokyo

With six salons across Singapore and over 15 years of beauty experience, Musee Platinum Tokyo is known for painless hair removal and advanced skincare treatments. The brand combines expertise with innovative solutions, emphasising safety, comfort, and non-invasive care across all services.

For more information or to book, visit www.musee-sg.com/en or follow @museeplatinum_sg on Instagram.

Source

TIANJIN, China, Dec. 22, 2025 /PRNewswire/ — A news report from China Daily:

The 2025 “A Date with China” international media delegation concluded a three-day visit to Tianjin on Dec 17, getting a glimpse of the city’s development in preserving intangible cultural heritages, driving cutting-edge technological innovations, and advancing global vocational education.

To get a taste of Tianjin’s vibrant intangible cultural heritage, the group visited Tianjin Pingju Opera Theatre, Guangdong Guild Hall, and Xiaoliyuan Crosstalk Teahouse, where they donned traditional opera costumes, practiced kuaiban (rhythmic bamboo clappers), and experienced the art of “speaking, imitating, teasing, and singing”.

On Ancient Culture Street, Italian blogger Andrea stepped up to the griddle and tried his hand at making jianbing guozi (Chinese pancake wrap), joking, “You may have seen Italians make pizza, but this is probably the first time you’ve seen an Italian make jianbing guozi.”

The group also experienced Clay Figure Zhang and saw a shadow puppetry performance of Journey to the West. Bruno Falci, a reporter from TeleSUR, said that foreign journalists eagerly want to understand these art forms, and seized every chance to deeply explore Chinese culture.

The international media group also got a firsthand experience of Tianjin’s technological vitality at industrial parks and tech enterprises. American blogger Dante Munoz showed great interest in cutting-edge products, trying out foldable tablets, AI chat assistant, and intelligent health robots.

“Chinese products are high-tech and reliable; enterprises grasp global needs well,” Munoz said, adding that he’s looking forward to better localized products.

The intelligent upgrading of Tianjin Metro Line 1 also amazed global guests. A 360-degree vehicle exterior image detection system can identify loose screws and foreign objects, while an intelligent vehicle operation and maintenance system monitors door operations, driving modes, and traction braking levels. This human-machine collaboration enhances efficiency and reduces maintenance costs.

At the Luban Workshop Experience Museum, the delegation learned about China’s global vocational education achievements. They met four Egyptian students majoring in computer numerical control. Student Ibrahim Maher said studying there boosted his growth and that he hoped to bring Chinese skills back to Egypt.

Luban Workshop is a world-renowned cooperation brand created by Tianjin, introduced by Wang Juan, director of International Exchange and Cooperation Department at Tianjin Light Industry Vocational Technical College. Now, 36 Luban Workshops exist in 30 countries, training talents for local development like Egypt’s industrialization. “Luban Workshops teach practical skills,” Italian blogger Andrea said. “China now exports not just products but professional skills — remarkable.”

Source

TAIPEI, Dec. 22, 2025 /PRNewswire/ — MCB Group, a Taiwan-based global manufacturer of premium nutritional powder ingredients, has further streamlined its operations into a full CDMO private-label provider, showcasing a range of trend-driven branded ingredients and turnkey total solutions at SupplySide Global 2025, aimed at capturing growth in next year’s booming market.

The focus on MCB’s new ingredients reflects insights generated through its AI-powered market platform, revealing a clear shift: sports nutrition is rapidly becoming part of everyday nutrition. Consumers now prefer convenient delivery forms—such as drink sachets, coffee mixes, and ready-to-drink beverages —to incorporate nutrients like creatine, MCT powder, and plant-based proteins into their daily routines.

The global sports nutrition market is expected to reach USD 75 billion with CAGR of 7.5% by 2030, according to Grand View Research. The United States accounts for the largest share of global sports nutrition products, has seen incredible growth from creatine and plant-based protein are also appealing to mainstream consumers, with significant opportunity for brands in meal replacement and hydration (electrolytes) products.

Targeted Superior Ingredients Delivery for Sports Nutrition

As a long-established nutritional ingredients provider, MCB’s branded ingredients MCTsolutions™ Micro-encapsulated MCT Oil Powders, are already widely used in global sport and nutritional brands. As the result of operation integration, MCB leveraged ingredients for sport nutrition with advanced technology, redefining creatine and plant-based protein from ingredient to comprehensive private-label solutions.

“We analyze global scientific data alongside MCB market research through an AI-powered platform, which revealed that creatine monohydrate is the most extensively studied and trusted form of creatine. However generic creatine faces limitations like poor water solubility, low bioavailability, and common digestive discomfort.” said Dr.Joseph Chiu, VP of health ingredient for MCB Taiwan. “To address these limitations, we have implemented a Hydrogel Delivery System in our instant creatine monohydrate, CreHytine™.”

MCB’s branded instant creatine monohydrate CreHytine™ innovated with Hydrogel Delivery System, encapsulating creatine monohydrate within a gum-based hydrogel matrix and buffering alkaline mineral (magnesium), remain high creatine content and improved bioavailability, key advancements include:

• Exceptional Purity >98% Creatine Monohydrate
  With advanced encapsulation and buffering technology, CreHytine™ maintains an industry-leading 98% pure creatine monohydrate content, addressing a common trade-off between functionality and active concentration.
• Instant Dissolution Performance
  Engineered as an instant-type creatine monohydrate, CreHytine™ achieves complete dispersion in approximately 8 seconds, significantly outperforming standard micronized creatine and enhancing consumer convenience in ready-to-mix applications.
• Ultra-Fine Particle Engineering
  With a particle size refined to 200–300 mesh, CreHytine™ instant creatine monohydrate goes beyond generic micronized creatine, contributing to faster dissolution, improved mouthfeel, and superior formulation flexibility across powder blends, gummy, and functional beverages.
• pH Stability with Alkaline Mineral Buffering
  The integration of magnesium-based alkaline mineral buffering helps stabilize creatine monohydrate under acidic conditions, supporting improved bioavailability while also reducing common gastrointestinal discomfort associated with conventional creatine supplementation.

High-performance creatine monohydrate is one of the fastest-growing product categories within sports nutrition driven by consumers’ ongoing to shift toward active and healthier lifestyles. 

Private-Label Solutions from Sport Nutrition to Daily Life

With the expansion of its CDMO and private-label business, MCB is leveraging proprietary ingredients to develop a series of private-label solutions for dynamic sports nutrition market, including creatine, electrolytes(hydration), and protein products (especially pea protein, which contain essential amino acids and clean protein source free from allergens).

Daily Sports Nutrition Private-label Solution

MCB has designed a full range of sports nutrition private-label concepts for everyday supplementation, incorporate its branded ingredient CreHytine™ Instant Creatine Monohydrate, a hydrogel creatine monohydrate addressed all the challenges of genetic creatine:

• Creatine + Electrolytes (Hydration Formula): Integrating high-purity creatine monohydrate with a balanced electrolyte complex. The electrolytes private-label formula support hydration, recovery, and performance during training and daily physical activity.
• Pre-Workout Creatine Formula: Uses pH-corrected buffered creatine monohydrate for superior ATP metabolism, and vitamins with natural caffeine give the body more energy for daily life and exercise.
• Women Creatine Formula: Optimized creatine monohydrate for fast dissolution and clean taste, women creatine private label with added collagen to enhance skin and joint elasticity for modern active female.

Lifestyle Protein Supplementation Private label

The innovative protein collection integrates functional ingredients into daily diets, protein supplementation with benefits:

• Clear Protein Water: A light, refreshing, and cost-effective alternative to clear whey protein, formulated for modern, on-the-go consumers seeking convenient daily protein intake.
• Functional Meal Replacement: Powered by plant-based pea protein and enhanced with CollaGEM™-V Vegan Collagen Alternative, this formulation provides complete nutritional support tailored for vegan and vegetarian.

These private-label offering in a variety dosage, such as sachet, pouch and jar, transform MCB’s ingredient innovations into complete, market-ready formula for brands to enter booming market.

Catering Solutions for a Growing Market

MCB are coming off the high-speed periods of new private-label development, 3-5 innovative ingredients can be rapidly developed annually and turned into 130+ ODM market-ready formulas.

Throughout SupplySide Global 2025, MCB reaffirmed its position as a trusted global CDMO+ partner from ingredient to solution, capable of transforming complex scientific breakthroughs into commercially viable, consumer-ready supplement turnkey solutions. With a clear focus on next year’s growth markets—particularly daily sports nutrition (creatine), functional hydration, and lifestyle protein.

Source

SEOUL, South Korea, Dec. 22, 2025 /PRNewswire/ — WePlay, the global flagship social entertainment platform under WEJOY PTE. LTD., officially announced the launch of its “Let’s Celebrate Christmas Together” campaign, running from December 19 to 25. As a social platform beloved by Gen Z users aged 18–25 around the world, this year’s Christmas celebration introduces not only highly interactive features such as the Voice Room Red Envelope Rain and the Christmas Wish Plaza, but also a special charity initiative titled “Let’s Make a Wish for the Dogs!”

Entertainment Meets Philanthropy: Every Interaction Carries Warmth

In the “Let’s Make a Wish for the Dogs!” charity segment, users can accumulate Warmth Points by sending themed gifts or purchasing lottery tokens. The collective kindness of the entire community contributes to a growing progress bar. Each time the bar reaches a new milestone, WePlay will donate additional supplies to City Without Stray Dogs.

The campaign aims to deliver a total of 615 kg of prescription dog food and 50 electronic training whistles, which will support better nutrition and behavioral training for rescued dogs—helping them adapt to social environments and increasing their chances of adoption.

Brand Vision: Bridging Virtual Interaction with Real-World Kindness

WePlay remains committed to its mission of “Making the world better through interaction.” The platform not only provides young people with a vibrant social playground, but also aims to bridge the passion of the virtual world with real-world social responsibility.

Jingci Zhao , Head of WePlay Korea, stated:
“The heart of WePlay’s charity work lies in using the warmth of social interaction to transmit the power of life. Through this Christmas initiative, we hope young users can feel that WePlay is not only a place to make friends and have fun, but also a space where simple interactions can come together to make a real-world impact. Every bag of prescription food and every training whistle represents our users’ love and respect for life.”

About WePlay

WePlay is the flagship social entertainment platform under WEJOY PTE. LTD., headquartered in Singapore. Featuring popular titles such as Space Werewolf, Guess My Drawing, and Mic Grab, WePlay aims to create a dynamic digital space that blends games, social interaction, and entertainment—helping young users connect effortlessly and build meaningful friendships.

Media Contact

Company: WEJOY PTE. LTD.
Contact: Peinan Qi
Email: qipeinan@wejoysg.com 
WePlay Website: https://weplayapp.com/

Source

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to:

• TLX591-CDx (Illuccix® in approved jurisdictions, ⁶⁸Ga-PSMA-11): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.
• TLX101-CDx (Pixclara®^[1], ¹⁸F-floretyrosine), PET imaging candidate for glioma: Following collaborative interactions with the FDA, finalizing NDA resubmission and expect to provide a further near-term update on FDA acceptance of the file.
• TLX250-CDx (Zircaix®^[1], ⁸⁹Zr-DFO-girentuximab), PET imaging candidate for ccRCC: Positive Type A meeting held with the FDA to align on remediation of CMC deficiencies identified in the CRL.

Further details on each of these updates is provided below.

Illuccix China Phase 3 Registration Study

Telix is pleased to announce positive top-line results from its Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of ⁶⁸Ga-PSMA-11) for prostate cancer imaging in Chinese patients. The Illuccix China^[2] trial met its primary endpoint of patient-level positive predictive value (PPV) for the detection of tumors in patients with biochemical recurrence (BCR) of prostate cancer following prior radical prostatectomy or radiation therapy. The study confirms that the clinical experience of TLX591-CDx PSMA-PET^[3] imaging in Chinese patients is comparable to that observed in patients studied elsewhere.

Illuccix China is a Phase 3 prospective, open-label, single-arm, multicenter study conducted in collaboration with Telix’s strategic commercial partner for the Greater China region, Grand Pharmaceutical Group Limited (Grand Pharma). The study in 140 patients delivered a strong result for the primary endpoint, with an overall patient-level PPV of 94.8% for the detection of tumors with TLX591-CDx (95% confidence interval [CI]: 85.9%, 98.2%), with the lower bound of the 95% CI (85.9%). The region-level PPV was 100.0% in the prostate bed and in the extra-pelvic soft tissue, lymph nodes, and organ metastases (non-bone); 94.7% in the pelvic region outside of the prostate bed, including lymph nodes; and 87.0% in bone metastases.

In the study, patients with suspected BCR were stratified into groups according to their baseline prostate specific antigen (PSA) levels. TLX591-CDx PSMA-PET imaging demonstrated high PPV in all patient groups, including at very low baseline PSA levels.

More than two-thirds (67.2%) of patients experienced a change in their treatment plan as a consequence of TLX591-CDx PSMA-PET imaging compared with the initial plan at baseline. This outcome confirms that PSMA-PET imaging with TLX591-CDx had a meaningful impact on clinical decision-making in Chinese patients, potentially leading to improved treatment strategies for participants with BCR. Final data from the study will be submitted for peer-reviewed publication.

Dr. David N. Cade, Group Chief Medical Officer, Telix, commented, “This is an outstanding result. The primary endpoint of the study was met decisively, with the positive predictive value significantly exceeding the performance threshold agreed with the Chinese regulator. Importantly, the high PPV was consistent even in patients with very low PSA values, and across differing metastatic locations, demonstrating broad clinical applicability. These compelling data will enable Telix and our partner Grand Pharma to submit a New Drug Application for Illuccix in China, a strategically important market.”

In China, more than 134,000 men were diagnosed with prostate cancer in 2022^[4], increasing by approximately 6% each year^[5]. In line with government policy supporting wider geographic access to nuclear medicine, the number of PET/CT cameras installed in China is expected to surpass 1,600 by the end of 2025^[6], compared with 133 in 2010^[7].

FDA Resubmission Update: TLX101-CDx

Telix advises that its New Drug Application (NDA) resubmission for TLX101-CDx, (Pixclara®^[1], ¹⁸F-floretyrosine) to the United States (U.S.) Food and Drug Administration (FDA), is progressing well. The Company has had collaborative interactions with the FDA around providing additional clinical data and a revised statistical analysis plan.

Following a productive Type A meeting to review the basis of the Complete Response Letter (CRL)^[8], Telix is currently finalizing its package for resubmission. The Company will provide a further near-term update when the resubmission has been filed and accepted by the FDA. The approved Expanded Access Program (EAP)^[9] remains active for TLX101-CDx, reflective of Telix’s commitment to serving patients.

FDA Resubmission Update: TLX250-CDx

Telix has recently participated in a Type A meeting to discuss the CRL it received following review of the Biologics License Application (BLA)^[10] for TLX250-CDx (Zircaix®^[1], ⁸⁹Zr-DFO-girentuximab). Telix believes it has reached alignment with the FDA on the remediation of identified deficiencies regarding the product’s chemistry, manufacturing, and controls (CMC) package, which formed the substantive basis of the CRL.

The FDA has collaboratively granted Telix an additional meeting in January to review Telix’s plan for the additional data requested to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial^[11] and the scaled-up manufacturing process intended for commercial use. Telix will provide a further update following receipt of the official FDA meeting minutes of both Type A meetings. The approved Expanded Access Program (EAP)^[12] remains active for TLX250-CDx, reflective of Telix’s commitment to serving patients.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA^[13].

TLX101-CDx is Telix’s PET imaging candidate for glioma, a rare and life-threatening brain cancer. TLX250-CDx is Telix’s PET imaging candidate for the diagnosis and characterization of clear cell renal cell carcinoma, the most common kidney cancer subtype. TLX101-CDx and TLX250-CDx have not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-CDx and the planned BLA resubmission for TLX250-CDx, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

Source